The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat the disease, according to a newly published study. The prospective, outcome-based study of 427 breast cancer patients showed the genomic test, which analyzes 70 key genes, accurately determines which patients are at low risk of breast cancer recurrence and can therefore safely choose not to undergo chemotherapy. Read more here.
Study mentioned: Drukker CA, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013 Jan 31. doi: 10.1002/ijc.28082. [Epub ahead of print] PMID: 23371464
No comments:
Post a Comment